Decoy Therapeutics Begins Trading Under DCOY
Decoy Therapeutics (formerly Salarius Pharmaceuticals) will begin trading on Nasdaq under ticker DCOY on January 8, 2026, the company announced January 7, 2026. The preclinical-stage biotech says its proprietary peptide-conjugate platform and AI-enabled discovery infrastructure will accelerate candidate selection as it advances a lead antiviral program with BARDA interest toward IND-enabling work, while pursuing partnerships and non-dilutive funding in a capital-efficient 2026 plan.
Key Points
- 1Renames to Decoy Therapeutics and begins Nasdaq trading under DCOY on January 8, 2026
- 2Leverages AI-enabled peptide-conjugate platform to accelerate candidate selection and reduce development complexity
- 3Positions lead antiviral for IND-enabling work with BARDA interest, enabling partnerships and non-dilutive funding opportunities
Scoring Rationale
Official company rebrand with BARDA interest and AI-enabled platform boosts credibility and relevance, but limited technical detail limits novelty.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems